Catheter Precision (VTAK) Net Equity Issued and Repurchased (2017 - 2026)

Catheter Precision (VTAK) has reported Net Equity Issued and Repurchased for 8 consecutive years, with $5.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Equity Issued and Repurchased rose 219.68% year-over-year to $5.0 million in Q2 2026; TTM through Jun 2026 was $9.3 million, a 89.79% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 19.19% from the prior year.
• Net Equity Issued and Repurchased was $5.0 million for Q2 2026 at Catheter Precision, up from $1.9 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $11.5 million in Q1 2023 and troughed at -$11.3 million in Q4 2023.
• A 5-year average of $2.5 million and a median of $2.0 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased slumped 92.37% in 2025 and jumped 219.68% in 2026, its largest moves.
• Over 5 years, Net Equity Issued and Repurchased stood at $400000.0 in 2022, then sank by 2915.5% to -$11.3 million in 2023, then jumped by 129.8% to $3.4 million in 2024, then slumped by 92.37% to $256000.0 in 2025, then surged by 1860.55% to $5.0 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $5.0 million (Q2 2026), $1.9 million (Q1 2026), and $256000.0 (Q4 2025), per Business Quant data.